The CAV2 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the CAV2 gene in the human 786-O renal cell carcinoma epithelial cell line. This pooled format preserves population-level heterogeneity, avoiding the biases of single-cell cloning and enabling robust functional studies in a cancer-relevant context.
The 786-O host cell line is a widely utilized human clear cell renal cell carcinoma model originally derived from a primary renal adenocarcinoma. These epithelial cells are characterized by constitutive activation of the PI3K-AKT and MAPK/ERK pathways, which drive proliferation and survival, and they lack functional VHL, leading to HIF stabilization. The 786-O background is extensively employed in renal cancer research, including studies of signal transduction, drug sensitivity, and metastasis.
Caveolin-2, encoded by CAV2, is a scaffolding protein that co-assembles with caveolin-1 to form caveolar invaginations essential for endocytosis, lipid trafficking, and signal compartmentalization. It directly interacts with caveolin-1, SRC family kinases, flotillin, integrins, and heterotrimeric G-proteins, contributing to caveola stability and function. Upstream, CAV2 expression and caveolar assembly are activated by SRC-mediated phosphorylation, cholesterol levels, and mechanical stress. Downstream, caveolin-2 modulates signal transduction from cell surface receptors including EGFR and integrins, leading to regulation of AKT, ERK1/2, and STAT3 signaling cascades. Consequently, CAV2 knockout disrupts caveolar architecture, impairs endocytic trafficking, and attenuates receptor-mediated proliferative and migratory signals.
In the 786-O human clear cell renal carcinoma background, CAV2 loss-of-function is particularly informative because ccRCC cells often exhibit aberrant caveolin expression and altered endocytic pathways. The knockout model impairs integrin-mediated adhesion and EGFR internalization, processes known to influence tumor cell migration, invasion, and survival. This cell population therefore serves as a relevant system to investigate how caveolar dysfunction contributes to oncogenic signaling, metastatic progression, and potential resistance to targeted therapies in renal cancer.
Researchers can utilize these polyclonal knockout cells in diverse assays, including cancer signal transduction studies, endocytosis and intracellular trafficking assays, nanoparticle uptake and drug delivery experiments, and investigations of tumor?Cstroma interactions. Standard validation techniques include western blotting and RT-qPCR to confirm CAV2 disruption, immunofluorescence to visualize caveolae loss, Transwell migration and invasion assays, fluorescent tracer uptake for endocytosis, and phospho-specific immunoblotting to assess changes in AKT, ERK, and STAT3 activation. For further information or to discuss custom gene-editing needs, please contact Ascent Research.
